Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25024452 | 0.92 | DDB1 (0.51) | DDB1CRBNDRD2DRD3HTR1A | |
| SCHEMBL30796794 | 0.88 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL26452361 | 0.88 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL25821980 | 0.87 | DDB1 (0.44) | DDB1CRBNDRD2DRD3HTR1A | |
| SCHEMBL30135745 | 0.87 | DDB1 (0.44) | DDB1CRBNDRD2DRD3HTR1A | |
| SCHEMBL30883435 | 0.86 | DRD2 (0.54) | DDB1CRBNDRD2DRD3 | |
| SCHEMBL27225200 | 0.86 | DRD2 (0.54) | DDB1CRBNDRD2DRD3 | |
| SCHEMBL30135838 | 0.85 | DDB1 (0.51) | DDB1CRBNDRD2DRD3HTR1A | |
| SCHEMBL29179838 | 0.84 | DDB1 (0.51) | DDB1CRBNHTR1AHTR7 | |
| SCHEMBL30135743 | 0.84 | CRBN (0.45) | DDB1CRBNDRD2DRD3KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-03-27 | — | — | US | disclosed |
| EP-4384521-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018237-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101025-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DDB1 132/4885CRBN 2136/4885DRD2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.